文献速递炎症性肠病

英夫利西单抗早期谷浓度与清除率预测急性重症溃疡性结肠炎英夫利西单抗挽救治疗后的结局:PREDICT-UC研究结果

Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC.
PubMed 文献 · Gastroenterology · 2025-07-21

本研究基于PREDICT-UC随机对照试验(NCT02770040),对135例激素难治性急性重症溃疡性结肠炎患者的681份血清和198份粪便样本进行英夫利西单抗浓度检测及药代动力学建模。结果显示,第3天血清英夫利西单抗浓度较低可预测第14天英夫利西单抗治疗失败及3个月内结肠切除术,高清除率患者从强化剂量中获益更多。

要点

  • 第3天血清英夫利西单抗浓度≤57.9 μg/mL预测3个月内结肠切除术的敏感性为83%、特异性为67%。
  • 第1至7天高清除率(≥0.62 L/d)患者接受初始10 mg/kg较5 mg/kg英夫利西单抗更可能应答(RR 1.50)。
  • 高清除率且对首剂无应答者,第二剂10 mg/kg较5 mg/kg的第14天应答率更高(38% vs 11%)。

核心结论

  • 英夫利西单抗早期浓度和清除率计算可预测急性重症溃疡性结肠炎的结局。
  • 这是首个证明高英夫利西单抗清除率可通过强化英夫利西单抗给药方案克服的研究。

研究设计与样本

  • PREDICT-UC随机对照试验(NCT02770040)比较强化与标准英夫利西单抗挽救治疗激素难治性急性重症溃疡性结肠炎。
  • 共采集135例患者的681份血清和198份粪便样本,英夫利西单抗浓度于试验结束后检测,清除率通过药代动力学建模得出。

主要发现

  • 第3天血清英夫利西单抗浓度较低预测第14天英夫利西单抗治疗失败(ROC曲线下面积=0.63;P=.043)及3个月内结肠切除术(ROC曲线下面积=0.77;P=.0027)。
  • 第3天血清英夫利西单抗浓度≤57.9 μg/mL对结肠切除术的敏感性为83%、特异性为67%、阳性预测值为24%、阴性预测值为97%。
  • 第1至7天高清除率(≥0.62 L/d)患者接受初始10 mg/kg较5 mg/kg英夫利西单抗更可能应答(风险比1.50;95%CI 1.01-2.23)。
  • 高清除率患者接受初始5 mg/kg较10 mg/kg英夫利西单抗的结肠切除术风险更高(HR 4.81;95%CI 1.09-21.37)。
  • 高清除率且对首剂英夫利西单抗无应答者,第二剂10 mg/kg较5 mg/kg的第14天应答率更高(38% vs 11%;风险比3.43;95%CI 1.05-11.19)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The role of infliximab therapeutic drug monitoring in acute severe ulcerative colitis (ASUC) management is unknown. We aimed to identify whether infliximab therapeutic drug monitoring is associated with ASUC outcomes. METHODS: Serum and stool samples were collected from patients enrolled in the PREDICT-UC randomized controlled trial (NCT02770040), which compared intensified and standard infliximab rescue in steroid-refractory ASUC. Infliximab levels measured after trial conclusion and clearance derived using pharmacokinetic modelling were correlated with outcomes. RESULTS: Infliximab levels were measured in 681 serum and 198 fecal samples from 135 patients. Lower day 3 serum infliximab levels predicted infliximab failure on day 14 (area under the receiver operator characteristic curve = 0.63; P = .043) and colectomy by 3 months (area under the receiver operator characteristic curve = 0.77; P = .0027); a threshold of ≤57.9 μg/mL had 83% sensitivity, 67% specificity, 24% positive predictive value, and 97% negative predictive value for colectomy. Patients with high clearance between day 1 and 7 (≥0.62 L/d) were more likely to respond to an initial 10 mg/kg vs 5 mg/kg infliximab dose (risk ratio, 1.50; 95% confidence interval [CI], 1.01-2.23), and had a higher risk of colectomy if they received an initial 5 mg/kg vs 10 mg/kg dose (HR, 4.81; 95% CI, 1.09-21.37). In patients with high clearance who did not respond to the first infliximab dose, day 14 response rate was higher with a second 10 mg/kg vs 5 mg/kg dose (38% vs 11%; risk ratio, 3.43; 95% CI, 1.05-11.19). Day 3 fecal infliximab levels correlated with endoscopic severity and was associated with day 7 nonresponse (P = .016). CONCLUSIONS: Early infliximab levels and clearance calculation can predict outcomes in ASUC. This is the first study to demonstrate that high infliximab clearance may be overcome by intensified infliximab dosing. (NCT02770040; Optimizing Infliximab Induction Therapy for Acute Severe Ulcerative Colitis).

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Li Wai Suen CFD, Choy MC, Con D, et al. Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC. Gastroenterology. 2025. PMID: 40701396. doi:10.1053/j.gastro.2025.07.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。